首页> 外国专利> A hybrid fusion protein transcription regulator to induce interferon target gene expression

A hybrid fusion protein transcription regulator to induce interferon target gene expression

机译:杂交融合蛋白转录调节子,诱导干扰素靶基因表达

摘要

New hybrid or chimeric fusion polypeptide transcription regulators which induce interferon target gene expression are provided for use in anti-viral and anti-proliferative applications. The hybrid fusion proteins comprise the p48 interferon regulatory factor protein, or a functional portion thereof, fused to a transcriptional activation domain (TAD), or a functional portion thereof. More specifically, the p48 interferon regulatory factor protein is fused to a STAT transcriptional activation do main (TAD) (p48-STAT TAD). A particular p48-STAT TAD is p48-S2C, in which S2C is the TAD of STAT2. Another p48- TAD is p48-VP16 TAD, in which p48 is fused to the transcriptional activation domain of the VP16 protein of Herpes Simplex Virus (HSV). The p48- TAD nucleic acid sequences and encoded polypeptides can be employed for anti-viral treatment and for the treatment of cancers, tumors and neoplastic diseases.
机译:提供了诱导干扰素靶基因表达的新的杂合或嵌合融合多肽转录调节剂,以用于抗病毒和抗增殖应用。杂合融合蛋白包含与转录激活结构域(TAD)融合的p48干扰素调节因子蛋白或其功能部分,或其功能部分。更具体地说,将p48干扰素调节因子蛋白与STAT转录激活主体(TAD)(p48-STAT TAD)融合。特定的p48-STAT TAD是p48-S2C,其中S2C是STAT2的TAD。另一个p48-TAD是p48-VP16 TAD,其中p48与单纯疱疹病毒(HSV)的VP16蛋白的转录激活结构域融合。 p48-TAD核酸序列和编码的多肽可用于抗病毒治疗以及用于癌症,肿瘤和赘生性疾病的治疗。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号